Nursing home residents are frail and thus are especially prone to medication side effects and drug interactions.

-   This paper describes a three-round Delphi process, resulting in a list of drugs, dosages, and drug combinations to be avoided in nursing home residents for safety reasons.

-   The list may serve as a tool in the prescribing process and in medication reviews.

-   The list may also be used in quality assessment and for research purposes.

Introduction {#S0002}
============

The nursing home (NH) population of Western countries has become increasingly frail and ill, with specific and extensive needs in terms of health care. A recent UK survey found that 56% of the residents in 38 NHs died within a year of admission \[[@C1]\]. In Norway, only 29% of long-term residencies in NHs exceeded two years' length in 2012 \[[@C2]\]. The majority of patients have multiple diseases with an average of four active diagnoses, four out of five residents have extensive needs for assistance in carrying out activities of daily living \[[@C2]\], and four out of five have dementia \[[@C3]\].

In general, the elderly population is more prone to medication side effects and drug--drug interactions \[[@C4]\]. Still there is often limited research evidence of effects and side effects, because most randomized, controlled trials on drug treatment are conducted in younger populations where comorbidities and polypharmacy are common exclusion criteria.

Various lists of explicit criteria for pharmacological inappropriateness have been developed to guide clinical practice and for assessing the extent of potentially inappropriate medication (PIM) use in the elderly \[[@C5],[@C6]\]. The Beers criteria were developed in the US in 1991 for NH residents \[[@C7]\] and later for a general population \[[@C8]\]. In Europe the STOPP-START criteria, designed for a general elderly population, were published in 2008 \[[@C11]\] and the German PRISCUS list was developed in 2010 \[[@C12]\]. The Norwegian General Practice (NORGEP) criteria are another list of explicit criteria for pharmacological inappropriateness, targeting home-dwelling elderly seen in general practice \[[@C13]\]. The NORGEP list consists of 36 statements including 21 single drugs and 15 drug--drug combinations. The list is partly based on the Beers' criteria and it was derived through a three-round Delphi consensus process carried out in 2006 by a large expert panel consisting of geriatricians, GP specialists, and clinical pharmacologists. According to the NORGEP criteria, one-third of the total population of home-dwelling elderly in Norway was exposed to at least one PIM over the course of one year in 2008 \[[@C14]\]. A study from Norwegian NHs based on 28 of the 36 NORGEP criteria revealed a prevalence of PIM of 31% \[[@C15]\].

Some studies have shown an impact of inappropriate drug regimens on health care outcomes like hospital admission rates \[[@C16],[@C17]\], self-perceived health status \[[@C18]\], and health-care utilization \[[@C19]\], while others have found no association between PIMs and the length of hospital stay \[[@C18]\]. Two studies found no association between PIMs and mortality \[[@C16],[@C20]\]. In one study, inappropriate medication use increased the risk of adverse drug events when measured by the STOPP criteria; however, when applying the Beers criteria the correlation was not significant \[[@C21]\]. There is a need for more evidence as to the clinical relevance of the different lists of explicit criteria when it comes to effect on patient-related health outcomes. In the present study we aimed at establishing an updated and clinically relevant tool for assessing medication use in NH residents.

Material and methods {#S0003}
====================

We conducted a three-round consensus process using the Delphi technique \[[@C22]\]. The Delphi technique is a structured communication technique where a panel of experts answers questions, most often in the form of a questionnaire, to which there are no scientifically proven correct answers \[[@C22]\]. The idea is that a group of experts, participating individually and anonymously, will give a more valid approach than experts one by one, and that consensus is reached through consecutive rounds in which participants are shown average responses made by the panel in previous rounds.

In August 2011 we invited by e-mail all members of the Norwegian Geriatrics Society (NGS, n = 122) and the Norwegian Society of Clinical Pharmacology (NFKF, n = 48) to participate. We also invited five pharmacists known to have particular expertise in medication safety, a convenience sample of NH physicians working in Oslo (n = 55), and all members of the Norwegian College of General Practitioners' Reference Group for NH medicine (n = 11). Altogether, the number of eligible doctors in the five groups was 241. A total of 92 doctors responded to the invitation, and 80 agreed to participate ([Figure 1](#F1){ref-type="fig"}).

![The Delphi process, setting, and participants. ^1^Nursing home physicians (n = 55), members of the Clinical Reference Group for Nursing Homes (n = 11), geriatricians (n = 122), clinical pharmacologists (n = 48), pharmacists (n = 5). Two of the doctors in the CRGNH were also nursing home physicians in Oslo and are represented in both groups here.](ipri-33-134.01){#F1}

The three rounds of the Delphi process were completed between August 2011 and March 2012. The survey was conducted via the software SurveyMonkey^®^ (Madison, WI, US), and the participants were sent an e-mail with a link to the survey. In first round they were exposed to 27 statements, suggesting criteria for inappropriate medication use in NH residents. The proposed criteria were based on the NORGEP criteria \[[@C13]\] and the knowledge and experience of the authors, who also carried out a comprehensive literature search for each suggested criterion. A few of the criteria from the NORGEP list have since their publication been taken off market and a few of them were shown to be of little clinical relevance in a subsequent pharmacoepidemiological national study \[[@C14]\] and these criteria were not included here. Other criteria given as single drug criteria in the NORGEP were here listed as drug classes (first-generation tricyclic antidepressants \[TCAs\], first-generation antihistamines, and neuroleptics). Each statement was presented with a brief explanation and up to three literature references. A commentary box was provided beneath each criterion. In addition, the participants were encouraged to suggest additional criteria and references.

A new literature search was performed before the authors decided whether or not to include criteria proposed by the panellists in the first round. The revised list of criteria was presented to the panellists in round two, in which average relevance scores from the first round were included. In the second round there was still room for comments but not for suggesting additional criteria. In the third round average scores for each criterion in round two were enclosed and the panellists were asked only to score without comments. A link for opting out was provided in each mail.

Main outcome was the panellists' evaluation of the clinical relevance in an NH setting of each statement as scored on a digital Likert scale from 1 (no clinical relevance) to 10 (highly clinically relevant) \[[@C23],[@C24]\].

Statistics {#S0004}
----------

For each criterion, degree of consensus was based on the average Likert score and corresponding standard deviation (SD). SDs described the degree of discordance through the three rounds. Statements were included in the final list if the mean score minus one SD exceeded 5 in round three.

Subgroup analyses were performed comparing scores made by the NH physician group with corresponding scores made by the rest of the panel. Because frequency distributions were skewed towards the right and thus were not normally distributed, Mann--Whitney U-tests were employed to analyse differences in consensus between the two groups. The participants were assumed independent of each other, since the survey was conducted via Internet and not in a face-to-face group. Because of the large number of statistical tests significance was set to p \< 0.01. Analyses were performed using IBM SPSS Statistics version 20.

Ethics {#S0005}
------

The study protocol was presented to and approved by the Norwegian Social Sciences Data Services (NSD). Since there was no intervention as such and all correspondence and comments were anonymous the NSD assessed that the study did not need explicit approval by the Regional Committee for Medical and Health Research Ethics.

Results {#S0006}
=======

We received altogether 92 responses from 34 Oslo nursing home physicians, nine members of the Reference Group for NH medicine (some of whom also were physicians in Oslo nursing homes), 13 members of NFKF, 38 members of NGF, and all five pharmacists. Of these, 80 participants agreed to take part in the survey out of which 52 completed all three rounds and 49 provided complete data (see [Figure 1](#F1){ref-type="fig"}). The first round comprised 27 statements to be scored while the second and third rounds held a total of 34 statements, seven of which were based on the panellists' suggestions in the first round. Five participants gave reasons for not completing the survey; the rest opted out by not responding to it. Of the 49 participants completing all three rounds, 15 (30.6%) were specialists in geriatrics, five (10.2%) specialists in clinical pharmacology, and five (10.2%) pharmacists, thus making up a group of 25. The other 24 (49.0%) respondents were NH physicians, some members of the General Practitioners' Reference Group for NH medicine.

All proposed criteria were included in the final list ([Table I](#TB1){ref-type="table"}). There was generally a high score for clinical relevance for most criteria, 26 of them receiving a mean score \> 8.0 for the first round the criterion was included ([Table II](#TB2){ref-type="table"}). For all criteria the relevance scores increased through the second and third rounds: 28 of the 34 criteria attained a final average score \> 9 in round three. For all criteria the SD was reduced from first to third round, reflecting fewer outliers at the lower end of the scale. Three criteria with an average score \< 8 in the first round had a final score \> 9 in the third round, namely non-steroidal anti-inflammatory drugs (NSAIDs) in general, anti-psychotics in absence of psychosis, and first generation of anti-histamines. Only the criterion regarding concurrent use of proton pump inhibitors (PPIs) and bisphosphonates still had a score \< 8 in round three.

###### 

Norwegian General Practice Nursing Home (NORGEP-NH) criteria for potentially inappropriate medication use in elderly (\> 70 years) nursing home residents.

  --------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------
  A: Single substance criteria                                                      Comments, adverse effects
   *Regular use should be avoided*                                                  
    1. Combination analgesic codeine/paracetamol                                    Poor long-term effects. Constipation, sedation, falls
    2. Tricyclic antidepressants (TCAs)^1^                                          Anticholinergic effects, cardiotoxicity
    3. Non-steroid anti-inflammatory drugs (NSAIDs)                                 High risk of side effects and interactions
    4. First-generation antihistamines^2^                                           Anticholinergic effects, prolonged sedation
    5. Diazepam                                                                     Over-sedation, falls, fractures
    6. Oxazepam: Dosage \> 30 mg/day                                                Over-sedation, falls, fractures
    7. Zopiklone: Dosage \> 5 mg/day                                                Over-sedation
    8. Nitrazepam                                                                   Over-sedation, falls, fractures
    9. Flunitrazepam                                                                Over-sedation, falls, fractures, addiction
    10. Chlometiazole                                                               Poor safety record. Risk of cardiopulmonary death
    11. Regular use of hypnotics                                                    Over-sedation, falls, fractures
  B: Combination criteria                                                           
   *Combinations to avoid*                                                          
    12. Warfarin + NSAIDs                                                           Increased risk of bleeding
    13. Warfarin + SSRIs/SNRIs^3^                                                   Increased risk of bleeding
    14. Warfarin + ciprofloxacin/ofloxacin/erythromycin/clarithromycin              Increased risk of bleeding
    15. NSAIDs/coxibs^4^ + ACE-inhibitors^5^/AT2-antagonists^6^                     Increased risk of kidney failure
    16. NSAIDs/coxibs + diuretics                                                   Reduced effect of diuretics, risk of heart and kidney failure
    17. NSAIDs/coxibs + glucocorticoids                                             Increased risk of bleeding, fluid retention
    18. NSAIDs/coxibs + SSRI/SNRIs                                                  Increased risk of bleeding
    19. ACE-inhibitors/AT2-antagonists + potassium or potassium-sparing diuretics   Increased risk of hyperkalaemia
    20. Beta blocking agents + cardioselective calcium antagonists                  Increased risk of atrioventricular block, myocardial depression, hypotension, orthostatism
    21. Erythromycin/clarithromycin + statins                                       Increased risk of adverse effects of statins
    22. Bisphosphonate + proton pump inhibitors                                     Increased risk of fractures
    23. Concomitant use of 3 or more psychotropics^7^                               Increased risk of falls, impaired memory
    24. Tramadol + SSRIs                                                            Risk of serotonin syndrome
    25. Metoprolol + paroxetine/fluoxetine/bupropion                                Hypotension, orthostatism
    26. Metformin + ACE-inhibitor AT2-antagonists + diuretics                       Risk of impaired renal function and metformin-induced lactacidosis, especially in dehydration
  C: Deprescribing criteria. Need for continued use should be reassessed^8^         
    27. Anti-psychotics (incl. "atypical" substances^9^)                            Frequent, serious side effects. Avoid long-term use for BPSD^10^
    28. Anti-depressants                                                            Limited effect on depression in dementia
    29. Urologic spasmolytics                                                       Limited effect for urinary incontinence in old age Risk of anticholinergic side effects
    30. Anticholinesterase inhibitors                                               Temporary symptomatic benefits only. Frequent side effects
    31. Drugs lowering blood pressure                                               Hypotension, orthostatism, falls
    32. Bisphosphonates                                                             Assess risk--benefit in relation to life expectancy
    33. Statins                                                                     Assess risk--benefit in relation to life expectancy
    34. Any preventive medicine                                                     Assess risk--benefit in relation to life expectancy
  --------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------

Notes: ^1^Amitriptyline, doxepine, chlomipramine, trimipramine, nortryptiline; ^2^dexchlorfeniramine, promethazine, hydroxyzine, alimemazine (trimeprazine); ^3^selective serotonin reuptake inhibitors/selective norepinephrine reuptake inhibitors; ^4^cyclooxygenase-2-selective inhibitors; ^5^angiotensin-converting enzyme inhibitors; ^6^angiotensin II receptor antagonists; ^7^from the groups centrally acting analgesics, antipsychotics, antidepressants, and/or benzodiazepines; ^8^this should be undertaken at regular intervals. For criteria 27--29, a safe strategy for re-evaluation is first to taper dosage, then stop the drug while monitoring clinical condition; ^9^risperidone, olanzapine, quetiapine, aripiprazole; ^10^behavioural and psychological symptoms in dementia.

###### 

Norwegian General Practice Nursing Home (NORGEP-NH) criteria for potentially inappropriate medication use in nursing home residents.^1^ Mean scores with standard deviations and final score.

  Criterion:                                                                                         Round 1 MS (SD)   Round 2 MS (SD)   Round 3 MS (SD)   Final score^2^
  -------------------------------------------------------------------------------------------------- ----------------- ----------------- ----------------- ----------------
  A: Single substance criteria. The following should be avoided for regular use whenever possible:                                                         
   1. Combination analgesic with codeine/paracetamol                                                 6.5 (2.3)         8.3 (1.8)         8.5 (1.4)         7.1
   2. Tricyclic antidepressants (TCAs) for depression                                                7.2 (2.1)         9.1 (1.2)         9.5 (0.7)         8.8
   3. NSAIDs                                                                                         8.8 (2.0)         9.8 (0.6)         9.8 (0.5)         9.3
   4. First-generation antihistamines                                                                7.6 (2.4)         8.6 (1.6)         9.3 (1.0)         8.3
   5. Diazepam                                                                                       9.1 (1.7)         9.6 (1.0)         9.7 (1.0)         8.7
   6. Oxazepam: Dosage \> 30 mg/day                                                                  8.8 (1.5)         9.4 (1.2)         9.6 (1.0)         8.6
   7. Zopiklone: Dosage \> 5 mg/day                                                                  7.6 (2.4)         8.1 (2.0)         8.5 (1.8)         6.7
   8. Nitrazepam                                                                                     8.7 (1.9)         9.5 (1.0)         9.7 (0.8)         9.1
   9. Flunitrazepam                                                                                  9.3 (1.5)         9.8 (0.6)         9.9 (0.2)         9.7
   10. Chlometiazole                                                                                 8.6 (1.9)         9.1 (1.2)         9.2 (1.3)         7.9
   11. Regular use of hypnotics                                                                      N/A^3^            8.5 (2.0)         9.2 (1.3)         7.9
  B: Combination criteria. The following drug combinations should be avoided whenever possible:                                                            
   12. Warfarin + NSAIDs                                                                             9.6 (1.1)         10.0 (0.1)        10.0 (0.3)        9.7
   13. Warfarin + SSRI/SNRI                                                                          7.3 (2.5)         7.8 (1.5)         8.1 (1.4)         6.7
   14. Warfarin + ciprofloxacin/ofloxacin/ erythromycin/ clarithromycin                              8.1 (2.4)         9.1 (1.3)         9.2 (1.1)         8.1
   15. NSAIDs/coxibs + ACE-inhibitors/AT2-antagonists                                                9.1 (1.3)         9.4 (1.1)         9.6 (1.0)         8.6
   16. NSAIDs/coxibs + diuretics                                                                     8.0 (2.2)         8.6 (1.8)         9.2 (1.6)         7.6
   17. NSAIDs/coxibs + glucocorticoids                                                               8.2 (2.1)         9.2 (1.3)         9.5 (0.9)         8.6
   18. NSAIDs/coxibs + SSRI/SNRIs                                                                    7.2 (2.5)         8.1 (1.9)         8.8 (1.5)         7.3
   19. ACE-inhibitors/AT2-antagonists + potassium or potassium-sparing diuretics                     8.4 (2.0)         9.2 (1.3)         9.6 (0.8)         8.8
   20. Beta blocking agents + cardioselective calcium antagonists                                    8.5 (2.0)         9.3 (1.2)         9.6 (0.8)         8.8
   21. Erythromycin/clarithromycin + statins                                                         8.3 (2.0)         9.5 (0.9)         9.6 (0.8)         8.8
   22. Bisphosphonate + proton pump inhibitors                                                       6.6 (2.4)         6.8 (2.1)         7.4 (1.8)         5.6
   23. Concomitant use of three or more psychotropic drugs                                           9.6 (0.7)         9.9 (0.5)         10.0 (0.1)        9.9
   24. Tramadol + SSRIs                                                                              N/A^2^            8.5 (1.8)         9.2 (0.9)         8.3
   25. Metoprolol + paroxetine/fluoxetine/bupropion                                                  N/A^2^            8.9 (1.1)         9.1 (1.0)         8.1
   26. Metformin + ACE-inhibitors/AT2-antagonists + diuretics                                        N/A^2^            8.4 (1.8)         8.6 (1.4)         7.2
  C: De-prescribing criteria. Need for continued use should be reassessed^4^                                                                               
   27. Anti-psychotics                                                                               7.6 (1.9)         9.5 (1.4)         9.7 (0.8)         8.9
   28. Anti-depressants                                                                              8.6 (0.9)         9.9 (0.2)         10.0 (0.0)        10.0
   29. Urologic spasmolytics                                                                         8.9 (1.6)         9.7 (0.7)         9.9 (0.4)         9.5
   30. Anticholinesterase inhibitors                                                                 9.4 (1.1)         9.8 (0.4)         9.9 (0.7)         9.2
   31. Drugs that lower blood pressure                                                               N/A^2^            9.9 (0.5)         10.0 (0.2)        9.8
   32. Bisphosphonates                                                                               N/A^2^            9.7 (0.9)         9.9 (0.4)         9.5
   33. Statins                                                                                       9.1 (1.3)         9.7 (0.9)         9.9 (0.5)         9.4
   34. General use of preventive medication                                                          N/A^2^            9.6 (1.0)         9.9 (0.4)         9.5

Notes: ^1^The clinical relevance for each of the criteria is scored (from 1 to 10) by a panel of experts during a three-round consensus process. Figures are mean scores with standard deviation, MS (SD). ^2^Final score (column to the right) is mean score in round 3 minus 1 SD in round 3. To be included on final NORGEP-NH list, final score should be \> 5. ^3^Not available, this denotes criteria first entered into the Delphi process in round 2. ^4^More details are given in [Table I](#TB1){ref-type="table"}.

Through all three rounds 27 criteria were assessed three times by the panel while seven were scored twice, resulting in 95 means altogether (see [Table II](#TB2){ref-type="table"}). When comparing mean scores made by NH physicians with those made by the group of geriatricians, clinical pharmacologists, and pharmacists (Mann--Whitney U-test with p \< 0.01 to correct for the large number of tests) we only found a significant but small difference for five out of 95 mean scores. For one criterion there was a difference in round 1 (p = 0.002) and 3 (p = 0.004), but not round 2 (p = 0.06), namely the combination of NSAIDs with selective serotonin reuptake inhibitors/selective norepinephrine reuptake inhibitors (SSRIs/SNRIs), where the nursing home physicians scored higher compared with the other group. The nursing home physicians were also more restrictive regarding NSAIDs in general (p = 0.001), statins (p = 0.001), and the combination of systemic NSAIDs/coxibs + systemic glucocorticoids (p = 0.008) in round 1 than the other group, but in later rounds no such difference was found.

Discussion {#S0007}
==========

This three-round Delphi process, carried out among 80 participants, resulted in a list of 34 criteria for potentially inappropriate medication use in NHs. Both the degree of consensus and the average scores for clinical relevance increased throughout the Delphi process. A corresponding trend was also seen in the NORGEP Delphi process \[[@C13]\]. A Delphi technique is said to be useful when a problem does not lend itself to precise analytical techniques, but can benefit from subjective judgements on a collective basis \[[@C22]\]. However, the initial 27 suggestions, and the seven criteria suggested by the panel, are all based on a combination of experience among both the authors and the panel and evidence from the literature. All suggestions have been scrutinized through literature searches and relevant references were provided to the panel during the consensus process.

The standard deviations of the means can be interpreted as a measure of the degree of discord among the participants. However, our data did not follow a normal distribution, as most participants' scores were in the high range (right skewed distribution), especially in round 3, thus the SD will be inflated and not give an exact measure of the variance \[[@C25]\]. Still, a larger SD implies that a larger number of participants scored well below the mean. The Delphi technique in itself can be said to be conservative in the respect that it takes quite a lot for a proposed criterion to be rejected. The main reasons for the Delphi method to fail are imposing monitor views and preconceptions upon the respondent group, and ignoring and not exploring disagreements \[[@C22]\]. In order to avoid falling into these traps and including criteria for which there was substantial discord, we decided that a criterion be included in the final list only if (mean --1SD) \> 5, so that not only was the mean score taken into consideration but also the degree of discord. In a case with a high degree of disagreement, as seen by a high SD, the average minus SD will thus be lower than in a case with a high general agreement (and thus a low SD). In this way, a controversial criterion will be less likely to be included in the list than a less controversial. Still no criterion was voted out through the three rounds.

Out of the 80 doctors who initially agreed to take part in the survey, 49 (61%) completed all three rounds. Of these 24 (49%) were nursing home physicians. The survey was lengthy, with a lot of text and many references, and this might have added to the withdrawal percentage. However, participants who completed all three rounds were in large part active throughout the process, providing numerous comments and suggestions for further references in both rounds one and two, thus giving the impression of an involved and independent panel.

It has been argued that one of the most critical aspects when designing a Delphi survey is the selection of qualified experts \[[@C22]\]. In some earlier surveys, among them the Beers consensus process and its later updates \[[@C7],[@C8],[@C10]\], the recruitment process differed from the present study in that the panel consisted of considerably fewer, hand-picked experts: 12 and six in the case of Beers criteria for NHs. The Delphi process leading to the NORGEP criteria, however, included a panel of 47 doctors \[[@C13]\]. At present there is no vocational training leading to a clinical speciality within NH medicine in Norway. Thus we do not know NH doctors' level of expertise and experience. To check for robustness with regard to this matter we tested the average scores and the development of consensus throughout the survey\'s three rounds for these participants versus the rest of the panel. Using the Mann--Whitney U-test with p \< 0.01 to correct for the large number of tests, we found only minor differences between the two groups of panellists. The final list of explicit criteria would have been unaltered had only either one of the two participant groups undertaken the survey.

The final 34 criteria can roughly be divided into three groups: single-substance criteria, drug--drug combination criteria, and criteria where regular consideration of "de-prescribing" is of uttermost importance in this population. The term "de-prescribing" can be defined as cessation of long-term therapy, supervised by a clinician \[[@C26]\]. It has been suggested that the term should be adopted internationally by researchers and practitioners engaged in this area \[[@C27]\]. Three criteria in this latter group concern preventive drug use when expected remaining life span is short: one concerning the use of preventive medication in general, the other two concerning the use of, respectively, bisphosphonates and statins. One can argue that the two latter criteria are redundant. However, since there was consensus to include all three criteria throughout the survey, they were included in the final list. A similar argument applies to using NSAIDs in different combinations, all of which could have been substituted by a single general criterion. However, since some of the combinations are particularly risky, the combination criteria still may serve a purpose in attracting attention to these potential threats.

The criterion concerning the combination of PPIs and bisphosphonates, suggested by one of the participants, was the only criterion with a mean score \< 8 in the final round. Because this represented relatively new knowledge at the time of the survey, the lower score can be viewed as healthy scepticism, as one could argue that more research was needed. After this study was completed, new research has strengthened the evidence for the clinical relevance of avoiding this combination, which is associated with increased risk for fractures \[[@C28],[@C29]\].

The criteria concerning concomitant use of SSRI/SNRI, and warfarin and NSAIDs respectively, do not distinguish between different SSRI/SNRI. However, different SSRI/SNRI represent a varying increase in the risk of bleeding when combined with anticoagulants due to differences in serotonin inhibition \[[@C30]\].

The Norwegian General Practice Nursing Home (NORGEP-NH) criteria resulting from this survey can be used as a reminder for NH physicians in their daily clinical work, and may also be useful for pharmacoepidemiological research and quality assessment work. In a previous study we found that one-third of the total population of home-dwelling elderly in Norway were exposed to at least one PIM over the course of one year, according to a modified version of the NORGEP criteria \[[@C14]\]. The present list, although primarily developed for the especially frail patients in nursing homes, can also be useful as a tool for GPs undertaking medication reviews for elderly patients outside institutions.

There is a need for more research on the effects of implementing the NORGEP-NH and similar lists with explicit criteria in clinical practice on outcomes like quality of life, morbidity, and mortality.
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